# Novavax Inc: financial statements, quarterly

NVAX · Nasdaq · CIK 1000694 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nvax.md) · [Financials](/companies/nvax/financials.md) · [Filings](/companies/nvax/filings.md) · [Insiders](/companies/nvax/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nvax/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [187](/filings/0001000694-24-000043.md) | [291 d](/filings/0001000694-26-000007.md) | [93.9](/filings/0001000694-25-000021.md) | [415](/filings/0001000694-25-000029.md) | [84.5](/filings/0001000694-25-000046.md) | [88.3 d](/filings/0001000694-26-000007.md) | [667](/filings/0001628280-26-030917.md) | [239](/filings/0001000694-26-000018.md) | [70.4](/filings/0001000694-25-000046.md) | [147 d](/filings/0001000694-26-000007.md) | [140](/filings/0001628280-26-030917.md) | [56.7](/filings/0001000694-26-000018.md) |
| Cost of revenue | $m | [98.9](/filings/0001000694-24-000043.md) | [155 d](/filings/0001000694-26-000007.md) | [59.2](/filings/0001000694-25-000021.md) | [46.2](/filings/0001000694-25-000029.md) | [60.6](/filings/0001000694-25-000046.md) | [36.7 d](/filings/0001000694-26-000007.md) | [14.1](/filings/0001628280-26-030917.md) | [15.3](/filings/0001000694-26-000018.md) | [21.5](/filings/0001000694-25-000046.md) | [22.1 d](/filings/0001000694-26-000007.md) | [30.7](/filings/0001628280-26-030917.md) | [14.2](/filings/0001000694-26-000018.md) |
| Research and development | $m | [106](/filings/0001000694-24-000043.md) | [165 d](/filings/0001000694-26-000007.md) | [92.7](/filings/0001000694-25-000021.md) | [107](/filings/0001000694-25-000029.md) | [87.2](/filings/0001000694-25-000046.md) | [104 d](/filings/0001000694-26-000007.md) | [88.9](/filings/0001628280-26-030917.md) | [79.2](/filings/0001000694-26-000018.md) | [98.3](/filings/0001000694-25-000046.md) | [75.9 d](/filings/0001000694-26-000007.md) | [95.5](/filings/0001628280-26-030917.md) | [70.7](/filings/0001000694-26-000018.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | [70.7](/filings/0001000694-25-000046.md) | [78.3 d](/filings/0001000694-26-000007.md) | [48.1](/filings/0001628280-26-030917.md) | [43.6](/filings/0001000694-26-000018.md) | [31.7](/filings/0001000694-25-000046.md) | [34.1 d](/filings/0001000694-26-000007.md) | [28.8](/filings/0001628280-26-030917.md) | [26.7](/filings/0001000694-26-000018.md) |
| Operating income | $m | [(126)](/filings/0001000694-24-000043.md) | [(184) d](/filings/0001000694-26-000007.md) | [(145)](/filings/0001000694-25-000021.md) | [161](/filings/0001000694-25-000029.md) | [(134)](/filings/0001000694-25-000046.md) | [(131) d](/filings/0001000694-26-000007.md) | [516](/filings/0001628280-26-030917.md) | [101](/filings/0001000694-26-000018.md) | [(178)](/filings/0001000694-25-000046.md) | [14.2 d](/filings/0001000694-26-000007.md) | [(15.4)](/filings/0001628280-26-030917.md) | [(54.9)](/filings/0001000694-26-000018.md) |
| Interest expense | $m | [2.9](/filings/0001000694-23-000055.md) | [4.1 d](/filings/0001000694-24-000007.md) | [4.1](/filings/0001000694-24-000031.md) | [4.1](/filings/0001000694-25-000029.md) | [4.2](/filings/0001000694-25-000046.md) | [7.6 d](/filings/0001000694-26-000007.md) | [5.7](/filings/0001628280-26-030917.md) | [5.5](/filings/0001000694-26-000018.md) | [5.5](/filings/0001000694-25-000046.md) | [5.8 d](/filings/0001000694-26-000007.md) | [4.9](/filings/0001628280-26-030917.md) | [5.7](/filings/0001000694-26-000018.md) |
| Income tax | $m | [(0.7)](/filings/0001000694-24-000043.md) | [1.7 d](/filings/0001000694-26-000007.md) | [2.3](/filings/0001000694-25-000021.md) | [2.2](/filings/0001000694-25-000029.md) | [(1.0)](/filings/0001000694-25-000046.md) | [7.4 d](/filings/0001000694-26-000007.md) | [1.2](/filings/0001628280-26-030917.md) | [0.9](/filings/0001000694-26-000018.md) | [(0.7)](/filings/0001000694-25-000046.md) | [0.4 d](/filings/0001000694-26-000007.md) | [1.0](/filings/0001628280-26-030917.md) | [1.7](/filings/0001000694-26-000018.md) |
| Net income | $m | [(131)](/filings/0001000694-24-000043.md) | [(178) d](/filings/0001000694-26-000007.md) | [(148)](/filings/0001000694-25-000021.md) | [162](/filings/0001000694-25-000029.md) | [(121)](/filings/0001000694-25-000046.md) | [(81.0) d](/filings/0001000694-26-000007.md) | [519](/filings/0001628280-26-030917.md) | [107](/filings/0001000694-26-000018.md) | [(202)](/filings/0001000694-25-000046.md) | [17.5 d](/filings/0001000694-26-000007.md) | [(9.5)](/filings/0001628280-26-030917.md) | [(53.4)](/filings/0001000694-26-000018.md) |
| Diluted EPS | $ per share | [(1.26)](/filings/0001000694-24-000043.md) | not reported | [(1.05)](/filings/0001000694-25-000021.md) | [0.99](/filings/0001000694-25-000029.md) | [(0.76)](/filings/0001000694-25-000046.md) | not reported | [2.93](/filings/0001628280-26-030917.md) | [0.62](/filings/0001000694-26-000018.md) | [(1.25)](/filings/0001000694-25-000046.md) | not reported | [(0.06)](/filings/0001628280-26-030917.md) | [(0.32)](/filings/0001000694-26-000018.md) |
| Basic EPS | $ per share | [(1.26)](/filings/0001000694-24-000043.md) | not reported | [(1.05)](/filings/0001000694-25-000021.md) | [1.09](/filings/0001000694-25-000029.md) | [(0.76)](/filings/0001000694-25-000046.md) | not reported | [3.22](/filings/0001628280-26-030917.md) | [0.66](/filings/0001000694-26-000018.md) | [(1.25)](/filings/0001000694-25-000046.md) | not reported | [(0.06)](/filings/0001628280-26-030917.md) | [(0.32)](/filings/0001000694-26-000018.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [651](/filings/0001000694-23-000055.md) | [569](/filings/0001000694-26-000007.md) | [481](/filings/0001000694-24-000031.md) | [680](/filings/0001000694-24-000035.md) | [574](/filings/0001000694-24-000043.md) | [530](/filings/0001000694-26-000007.md) | [263](/filings/0001000694-25-000021.md) | [254](/filings/0001000694-25-000029.md) | [268](/filings/0001000694-25-000046.md) | [241](/filings/0001000694-26-000018.md) | [228](/filings/0001628280-26-030917.md) | [191](/filings/0001000694-26-000018.md) |
| Current assets | $m | [1,007](/filings/0001000694-23-000055.md) | [1,144](/filings/0001000694-25-000004.md) | [727](/filings/0001000694-24-000031.md) | [1,203](/filings/0001000694-24-000035.md) | [1,104](/filings/0001000694-24-000043.md) | [1,129](/filings/0001000694-26-000007.md) | [868](/filings/0001000694-25-000021.md) | [920](/filings/0001000694-25-000029.md) | [975](/filings/0001000694-25-000046.md) | [978](/filings/0001000694-26-000018.md) | [851](/filings/0001628280-26-030917.md) | [771](/filings/0001000694-26-000018.md) |
| Total assets | $m | [1,657](/filings/0001000694-23-000055.md) | [1,797](/filings/0001000694-25-000004.md) | [1,354](/filings/0001000694-24-000031.md) | [1,819](/filings/0001000694-24-000035.md) | [1,712](/filings/0001000694-24-000043.md) | [1,560](/filings/0001000694-26-000007.md) | [1,293](/filings/0001000694-25-000021.md) | [1,337](/filings/0001000694-25-000029.md) | [1,180](/filings/0001000694-25-000046.md) | [1,177](/filings/0001000694-26-000018.md) | [1,043](/filings/0001628280-26-030917.md) | [956](/filings/0001000694-26-000018.md) |
| Current liabilities | $m | [1,469](/filings/0001000694-23-000055.md) | [1,635](/filings/0001000694-25-000004.md) | [804](/filings/0001000694-24-000031.md) | [1,158](/filings/0001000694-24-000035.md) | [1,181](/filings/0001000694-24-000043.md) | [1,154](/filings/0001000694-26-000007.md) | [422](/filings/0001000694-25-000021.md) | [389](/filings/0001000694-25-000029.md) | [430](/filings/0001000694-25-000046.md) | [460](/filings/0001000694-26-000018.md) | [342](/filings/0001628280-26-030917.md) | [331](/filings/0001000694-26-000018.md) |
| Total liabilities | $m | [2,336](/filings/0001000694-23-000055.md) | [2,514](/filings/0001000694-25-000004.md) | [2,221](/filings/0001000694-24-000031.md) | [2,250](/filings/0001000694-24-000035.md) | [2,239](/filings/0001000694-24-000043.md) | [2,184](/filings/0001000694-26-000007.md) | [1,369](/filings/0001000694-25-000021.md) | [1,299](/filings/0001000694-25-000029.md) | [1,337](/filings/0001000694-25-000046.md) | [1,304](/filings/0001000694-26-000018.md) | [1,188](/filings/0001628280-26-030917.md) | [1,146](/filings/0001000694-26-000018.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [244](/filings/0001000694-26-000018.md) | [291](/filings/0001628280-26-030917.md) | [291](/filings/0001000694-26-000018.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(678)](/filings/0001000694-24-000043.md) | [(717)](/filings/0001000694-26-000007.md) | [(867)](/filings/0001000694-25-000029.md) | [(432)](/filings/0001000694-25-000046.md) | [(526)](/filings/0001000694-25-000046.md) | [(624)](/filings/0001000694-26-000018.md) | [(75.6)](/filings/0001000694-26-000018.md) | [37.6](/filings/0001000694-26-000018.md) | [(157)](/filings/0001000694-25-000046.md) | [(128)](/filings/0001000694-26-000018.md) | [(145)](/filings/0001000694-26-000018.md) | [(191)](/filings/0001000694-26-000018.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(39.7) d](/filings/0001000694-24-000043.md) | [(177) d](/filings/0001000694-26-000007.md) | [(83.6)](/filings/0001000694-25-000021.md) | [314 d](/filings/0001000694-25-000029.md) | [(145) d](/filings/0001000694-25-000046.md) | [(173) d](/filings/0001000694-26-000007.md) | [(186)](/filings/0001628280-26-030917.md) | [(127) d](/filings/0001000694-26-000018.md) | [108 d](/filings/0001000694-25-000046.md) | [(39.5) d](/filings/0001000694-26-000007.md) | [(32.4)](/filings/0001628280-26-030917.md) | [(72.8) d](/filings/0001000694-26-000018.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [78.3](/filings/0001000694-23-000055.md) | [86.2](/filings/0001000694-24-000031.md) | [104](/filings/0001000694-24-000035.md) | [103](/filings/0001000694-24-000043.md) | [140](/filings/0001000694-25-000021.md) | [166](/filings/0001000694-25-000029.md) | [160](/filings/0001000694-25-000046.md) | [178](/filings/0001628280-26-030917.md) | [177](/filings/0001000694-26-000018.md) | [162](/filings/0001000694-25-000046.md) | [163](/filings/0001628280-26-030917.md) | [165](/filings/0001000694-26-000018.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 164,945,726 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001000694-26-000018.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.